Lisa M. McShane

Also affiliated with National Cancer Institute

Biochemistry, Genetics and Molecular BiologyMedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.8Author DataRank

Indexed papers

9in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 9 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges

BMC Medicine(2023)10.1186/s12916-023-02858-y

Top 10%

2.1DataRank

Top 10%92 citations

Riccardo De Bin, Axel Benner, Federico Ambrogi, Lara Lusa, Anne‐Laure Boulesteix +7 more

Papers

Driven by 43 papers — median percentile 0. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges

BMC Medicine(2023)10.1186/s12916-023-02858-y

Top 10%

2.1DataRank

Top 10%92 citations

Riccardo De Bin, Axel Benner, Federico Ambrogi, Lara Lusa, Anne‐Laure Boulesteix +7 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

1.3DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa201

N/A

0.995DataRank · unranked

757 citations

Samuel Leung, David L. Rimm, Andrew Dodson, Balázs Ács, Sunil Badve +17 more

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository

Journal of Translational Medicine(2021)10.1186/s12967-021-02936-w

N/A

0.940DataRank · unranked

527 citations

Ming‐Chung Li, Mariam M. Konaté, Li Chen, Biswajit Das, Chris Karlovich +5 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0.817DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

Cancer Cell(2020)10.1016/j.ccell.2020.10.015

N/A

0.698DataRank · unranked

104 citations

Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton +41 more

Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group

Clinical Chemistry(2020)10.1093/clinchem/hvaa164

N/A

0.691DataRank · unranked

99 citations

Angela Silvestro, J. Carl Barrett, Kelli Bramlett, Darya Chudova, Ina L. Deras +15 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0.678DataRank · unranked

91 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0.571DataRank · unranked

44 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products

Molecular Oncology(2020)10.1002/1878-0261.12849

N/A

0.510DataRank · unranked

29 citations

Simarjeet Negi, Laura M. Yee, Jason R. Evans, Tanja Grkovic, Alida Palmisano +6 more

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0471

N/A

0.464DataRank · unranked

21 citations

Michael W. Lloyd, Soner Koc, Yvonne A. Evrard, Lisa M. McShane, Michael T. Lewis +29 more

Registering Diagnostic and Prognostic Trials of Tests: Is It the Right Thing to Do?

Clinical Chemistry(2014)10.1373/clinchem.2014.226100

N/A

0.457DataRank · unranked

20 citations

John P. A. Ioannidis, Kurtis R. Bray, Lisa M. McShane, Robert M. Golub, Lotty Hooft +3 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0.457DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3087

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray +13 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek

Clinical Trials(2023)10.1177/17407745231169692

N/A

0.312DataRank · unranked

7 citations

Mark D. Rothmann, Thomas R. Fleming, Lisa M. McShane

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0.269DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

JCO Precision Oncology(2024)10.1200/po.24.00327

N/A

0.260DataRank · unranked

4 citations

Opeyemi A. Jegede, David M. Jackman, James A. Zwiebel, Robert J. Gray, Victoria Wang +17 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0.241DataRank · unranked

4 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort

JCO Precision Oncology(2024)10.1200/po-24-00493

N/A

0.208DataRank · unranked

3 citations

Elizabeth Codd, Rashi Purohit, Beatrice Melli, Prinjali Kalyan, Jo Anne Fordham +10 more

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2560

Top 78%

0.104DataRank

Top 78%1 citations

Jennifer L. Silhavy, Jennifer S. LoCoco, Biswajit Das, Sorena Rahmanian, Ting-Chia Chang +15 more

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

JCO Precision Oncology(2024)10.1200/po.23.00454

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Helena A. Yu, Lecia V. Sequist, Christine M. Lovly, Edith P. Mitchell +17 more

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

JCO Precision Oncology(2024)10.1200/po-24-00514

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Andrew Poklepovic, Eric A. Collisson, James A. Zwiebel, Robert J. Gray +14 more

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

European Journal of Cancer(2022)10.1016/s0959-8049(22)01023-1

N/A

0.104DataRank · unranked

1 citations

Zeyuan Song, Scott Gettinger, Edith P. Mitchell, JJ Wright, Jeff Moscow +14 more

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188

Top 78%

0.104DataRank

Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Discovery of gene fusions in driver-negative NCI-MATCH screening samples.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3112

N/A

0.104DataRank · unranked

1 citations

A. John Iafrate, Chris Karlovich, P. Mickey Williams, Jeffrey Sklar, Lisa M. McShane +4 more

Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts

Scientific Reports(2022)10.1038/s41598-022-23693-w

N/A

0DataRank · unranked

4 citations

Ming‐Chung Li, Lisa M. McShane, Yingdong Zhao, Mariam M. Konaté

Sample size methods for evaluation of predictive biomarkers

Statistics in Medicine(2022)10.1002/sim.9412

N/A

0DataRank · unranked

6 citations

Lisa M. McShane, Kevin K. Dobbin

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Epigenetics(2024)10.1080/15592294.2024.2309824

N/A

0DataRank · unranked

6 citations

Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker +4 more

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa061

N/A

0DataRank · unranked

33 citations

Lou Staudt, Naoko Takebe, David A. Wheeler, Linghua Wang, Maria Cardenas +34 more

Evaluating clinical utility of comprehensive genomic profiling—challenges and opportunities

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae237

N/A

0DataRank · unranked

2 citations

Lyndsay N. Harris, Lisa M. McShane

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V

European Journal of Cancer(2022)10.1016/s0959-8049(22)01026-7

N/A

0DataRank · unranked

3 citations

Zeyuan Song, A. Poklepovic, Eric A. Collisson, Edith P. Mitchell, James Zweibel +15 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3035

N/A

0DataRank · unranked

0 citations

Amanda Peach, D. A. HOWELL, Biswajit Das, Rini Pauly, Ting-Chia Chang +14 more

Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products

BMC Cancer(2022)10.1186/s12885-022-09580-7

N/A

0DataRank · unranked

5 citations

Simarjeet Negi, Lisa M. McShane, Yingdong Zhao, Julia Krushkal, Hari Sankaran

Lisa M. McShane

Indexed papers

Top data-sharing exemplar

Papers